Dirk B. Mendel

Spark Therapeutics (United States) — United States

Medicine · Health Sciences

46h-index11.7kcitations92works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Influenza Virus Research Studies(18), Receptor Mechanisms and Signaling(12), Chemical Synthesis and Analysis(11), Estrogen and related hormone effects(10), Monoclonal and Polyclonal Antibodies Research(10)

Publications92 total

On the Way to the Clinic
2023
<i>CCR</i> 20th Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib—A Look Back
Clinical Cancer Research·2015· 5 cited
Abstract 4501: Sensitivities of kinase inhibitors of BCR signaling are correlated with the BCR signaling pathway activities in DLBCL and CLL
Cancer Research·2014
Comparison of AMG 416 and cinacalcet in rodent models of uremia
BMC Nephrology·2014· 25 citedOpen Access
Interrogation Of Signaling Networks In B Cell Malignancies To Improve Classification Of Patient Subsets For Targeted Therapy
Blood·2013
Translational sciences approach to RSV vaccine development
Expert Review of Vaccines·2013· 13 cited
Pharmacology of AMG 416 (Velcalcetide), a Novel Peptide Agonist of the Calcium-Sensing Receptor, for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
Journal of Pharmacology and Experimental Therapeutics·2013· 111 cited
Abstract 5582: Interrogation of signaling networks in DLBCL to improve classification of patient subsets for targeted therapy.
Cancer Research·2013
Abstract 3484: CTC enumeration and molecular characterization in a Phase 1 study of IGF-1 and IGF-2 inhibition by MEDI-573.
Cancer Research·2013
Preclinical PK and PD Relationship for KAI-4169, a Novel Calcimimetic
2011
KAI-4169, a Novel Calcimimetic for the Treatment of Secondary Hyperparathyroidism
2011· 1 cited
Non-ATP-competitive kinase inhibitors – enhancing selectivity through new inhibition strategies
Expert Opinion on Drug Discovery·2008· 15 cited
The melanoma inhibitory activity (MIA) protein is an early indicator for therapeutic response in preclinical melanoma models
Cancer Research·2007
Novel Robust Hepatitis C Virus Mouse Efficacy Model
Antimicrobial Agents and Chemotherapy·2006· 35 citedOpen Access
CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice
Clinical Cancer Research·2006· 66 cited
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity
Molecular Cancer Therapeutics·2006· 102 cited
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248
Molecular Cancer Therapeutics·2006· 109 citedOpen Access
CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models
Cancer Research·2006· 14 cited
CHIR-258 Efficacy in a Newly Developed Preclinical Bone Marrow Model of t(4;14) Multiple Myeloma.
Blood·2005· 1 cited
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
PubMed·2003· 497 cited
page 1 of 5Next →

Frequent Co-authors

Julie M. Cherrington(12), Choung U. Kim(8), Alexander Laird(7), Allan Munck(7), Willard Lew(6), Matthew A. Williams(6), Chun Y. Tai(6), Paul A. Escarpe(6), Katherine G. Moss(5), Jack E. Bodwell(5), James G. Christensen(4), Guangmin Li(4), Randall Schreck(4), Gerald McMahon(4), Lijun Zhang(4), Gerald R. Crabtree(4), Lynda I. Smith(4), Xiaohua Xin(3), Robert A. Blake(3), Norbert Bischofberger(3)